In this article, we will be looking at the 5 best one dollar stocks to buy now. If you want to see our detailed analysis of penny stocks, go directly to the 10 Best One Dollar Stocks to Buy Now.
5. Rockwell Medical, Inc. (NASDAQ: RMTI)
Stock Price as of July 16: $0.74
Number of Hedge Fund Holders: 4
Rockwell Medical, Inc. (NASDAQ: RMTI) ranks 5th on the list of 10 best one dollar stocks to buy now. The Michigan-based biopharmaceutical firm sells treatment products and therapies for chronic kidney disease. In addition, Rockwell Medical, Inc. (NASDAQ: RMTI) creates therapeutic candidates for acute heart failure treatment and infusion therapy.
In February, H.C. Wainwright analyst Raghuram Selvaraju maintained a Buy rating on Rockwell Medical, Inc. (NASDAQ: RMTI) and reduced its price target to $5.50 from $9 previously. This, according to the analyst, is related to the relatively low penetration of anemia therapy for dialysis patients, especially Triferic AVNU. The latest price target still presents a strong upside to the current price of the stock.
In June, Rockwell Medical, Inc. (NASDAQ: RMTI) renewed its distribution agreement with Nipro Medical Corporation for three years, until May 2024, enabling RMTI to provide dialysis concentrates to countries throughout the Caribbean and Latin America.
The company has a market cap of $69 million. In the first quarter of 2021, Rockwell Medical, Inc. (NASDAQ: RMTI) had an EPS of -$0.08, beating estimates by $0.01. The company’s revenue in the first quarter came in at $15.5 million, down from $15.9 million in the same period in 2020.
At the end of the first quarter of 2021, 4 hedge funds in the database of Insider Monkey held stakes worth $2.52 million in Rockwell Medical, Inc. (NASDAQ: RMTI), down from 5 in the previous quarter worth $2.27 million.
Like Novavax, Inc. (NASDAQ: NVAX), Amazon.com, Inc. (NASDAQ: AMZN), Apple Inc. (NASDAQ: AAPL), and Sundial Growers Inc. (NASDAQ: SNDL), Rockwell Medical, Inc. (NASDAQ: RMTI) is a good stock pick for long-term gains, according to market analysts.
4. Regulus Therapeutics Inc. (NASDAQ: RGLS)
Stock Price as of July 16: $0.71
Number of Hedge Fund Holders: 6
Regulus Therapeutics Inc. (NASDAQ: RGLS) ranks 4th on the list of 10 best one dollar stocks to buy now. The San Diego-based clinical-stage biopharmaceutical company develops microRNAs therapeutics for cancer, metabolic disease, inflammatory disease, and fibrosis.
After the first-quarter results, H.C. Wainwright maintained a Buy rating on Regulus Therapeutics Inc. (NASDAQ: RGLS) and lifted the price target to $2 from $1.5, citing promising positive topline data from the first batch of the Phase 1b trial of RGLS4326 for the treatment of patients with autosomal dominant polycystic kidney disease.
The company has a market cap of $53 million. In the first quarter of 2021, Regulus Therapeutics Inc. (NASDAQ: RGLS) had an EPS of -$0.08, beating estimates by $0.01. As of March 31, 2021, Regulus Therapeutics Inc. (NASDAQ: RGLS) had $31.6 million in cash and cash equivalents, up from $31.1 million in the fourth quarter of 2020.
At the end of the first quarter of 2021, 6 hedge funds in the database of Insider Monkey held stakes worth $14.9 million in Regulus Therapeutics Inc. (NASDAQ: RGLS), up from 4 in the previous quarter worth $11.9 million.
3. Isoray, Inc. (NYSE: ISR)
Stock Price as of July 16: $0.70
Number of Hedge Fund Holders: 4
Isoray, Inc. (NYSE: ISR) ranks 3rd on the list of 10 best one dollar stocks to buy now. The Washington-based medical device company manufactures isotope-based medical products and devices for cancer therapies. The company manufactures radioactive seeds to treat malignant diseases like head and neck, brain, prostate, and lung cancers.
In February, Lake Street analyst Frank Takkinen initiated Isoray, Inc. (NYSE: ISR) with a Buy rating and a $3 price target. The analyst commented that the Isoray, Inc.’s (NYSE: ISR) radiation isotope Cesium-131, for tumor treatment, as well as a January 2022 reimbursement adjustment, will boost the use of brachytherapy seeds for prostate cancer treatment.
The company has a market cap of $99 million. In the first quarter of 2021, Isoray, Inc. (NYSE: ISR) had an EPS of -$0.01. The company’s revenue for the third quarter of fiscal 2021 came in at $2.60 million, down from $2.88 million in the same period in 2020, but increased 10% sequentially from the previous quarter. Isoray, Inc. (NYSE: ISR) shares rose 56% year to date.
At the end of the first quarter of 2021, 4 hedge funds in the database of Insider Monkey held stakes worth $3.76 million in Isoray, Inc. (NYSE: ISR), up from 2 in the previous quarter worth $650,000.
2. AzurRx BioPharma, Inc. (NASDAQ: AZRX)
Stock Price as of July 16: $0.68
Number of Hedge Fund Holders: 2
AzurRx BioPharma, Inc. (NASDAQ: AZRX) ranks 2nd on the list of 10 best one dollar stocks to buy now. The Florida-based clinical-stage biopharmaceutical company develops non-systemic therapies for gastrointestinal diseases. The first patient in Phase 2 clinical trial of oral niclosamide to treat COVID-19 gastrointestinal infections was dosed in June by AzurRx BioPharma, Inc. (NASDAQ: AZRX). The trial’s topline results are expected in the first quarter of 2022.
In April, H.C. Wainwright analyst Yi Chen maintained a Buy rating on AzurRx BioPharma, Inc. (NASDAQ: AZRX) and reduced the price target to $2.50 from $3.50. The analyst forecasted a moderately lower probability of endorsement for AzurRx BioPharma, Inc.’s exocrine pancreatic insufficiency treatment, MS1819, down to 60% from 65%, and pushed back potential market entry to 2024 from 2023.
The company has a market cap of $53.4 million. In the first quarter of 2021, AzurRx BioPharma, Inc. (NASDAQ: AZRX) had an EPS of -$0.14, up 30% year over year, but missing estimates by $0.07. The company had roughly $6.1 million in cash and cash equivalents as of December 31, 2020.
At the end of the first quarter of 2021, 2 hedge funds in the database of Insider Monkey held stakes worth $143,000 in AzurRx BioPharma, Inc. (NASDAQ: AZRX), up from 1 in the previous quarter worth $181,000.
1. Gold Standard Ventures Corp (NYSE: GSV)
Stock Price as of July 16: $0.56
Number of Hedge Fund Holders: 4
Topping the list of the 10 best one dollar stocks to buy now is Gold Standard Ventures Corp (NYSE: GSV). The Canadian gold exploration company operates in Nevada to establish district-scale and other gold-bearing resource extraction properties. Gold Standard Ventures Corp (NYSE: GSV) owns more than 21,000 hectares of land on the Carlin Trend, second only to Nevada Gold Mines, for the development of the South Railroad Project.
In June, Gold Standard Ventures Corp (NYSE: GSV) was given a Speculative Buy rating and a $1.50 price target by Canaccord analyst Tom Gallo. According to analyst Tom Gallo, the preliminary feasibility assessment for the company’s South Railroad project “presents a de-risked, advanced understanding of the resource model”. In addition, Alex Terentiew of Stifel Nicolaus has resumed coverage of Gold Standard Ventures with a Buy rating and a price target of $1.70.
Gold Standard Ventures Corp (NYSE: GSV) announced in May that the exploration and development program for 2021 will be focused on testing for extensions to both Pinion and Dark Star, to increase the size of the pits and expand the project’s viability.
The company has a market cap of $191 million. In the first quarter of 2021, Gold Standard Ventures Corp (NYSE: GSV) had an EPS of -$0.01, in line with the estimates. As of March 31, 2021, the company had total assets of CA$297,768,500, up from CA$231,336,520 in the same period in 2020.
At the end of the first quarter of 2021, 4 hedge funds in the database of Insider Monkey held stakes worth $23.1 million in Gold Standard Ventures Corp (NYSE: GSV), down from 8 in the previous quarter worth $15.2 million.
You can also take a peek at the 10 Best Blue Chip Dividend Stocks Hedge Funds Are Buying and Beyond GameStop: Reddit’s WallStreetBets is Now Targeting These 10 Stocks.
